-

11:46:50 PM

RCEL Stock News

RCEL - AVITA Medical Inc

05/12/22 4:14 PM

Nasdaq : RCEL

earnings

AVITA Medical Reports First Quarter 2022 Financial Results

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “ Company ”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for

RHEA-AI

neutral

05/09/22 4:01 PM

Nasdaq : RCEL

RECELL® System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple

RHEA-AI

neutral

04/28/22 4:01 PM

Nasdaq : RCEL

earnings

AVITA Medical to Announce First Quarter 2022 Financial Results

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,

RHEA-AI

neutral

04/21/22 9:00 AM

Nasdaq : RCEL

management

Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple

RHEA-AI

neutral

04/04/22 8:00 AM

Nasdaq : RCEL

RECELL® System Data to be Presented at the American Burn Association Annual Meeting

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing

RHEA-AI

neutral

03/23/22 4:01 PM

Nasdaq : RCEL

clinical trial

RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,

RHEA-AI

neutral

03/21/22 4:01 PM

Nasdaq : RCEL

AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables

RHEA-AI

neutral

03/02/22 4:01 PM

Nasdaq : RCEL

Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that

RHEA-AI

positive

02/28/22 4:01 PM

Nasdaq : RCEL

earnings

AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results

AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “ Company ”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for

RHEA-AI

positive

02/23/22 4:28 PM

Nasdaq : RCEL

partnership

The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,

RHEA-AI

positive

1 2 3 4 5 6 Next

RCEL Data

IndustrySurgical and Medical Instrument Manufacturing
Websiteavitamedical.com
Security nameAVITA Medical Inc
Issue typecs
SectorManufacturing
Sic code3841
Employees2021
Tags
- Health Technology
- Biotechnology
- Medical Specialties

About AVITA Medical Inc

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical's patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient's skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.